NASDAQ:VTVT - vTv Therapeutics Stock Price, Price Target & More

$2.0850 -0.02 (-0.95 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$2.0850
Today's Range$1.90 - $2.33
52-Week Range$0.65 - $8.40
Volume3.41 million shs
Average Volume3.34 million shs
Market Capitalization$69.23 million
P/E Ratio-1.25
Dividend YieldN/A
Beta1.74

About vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics logovTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.

Receive VTVT News and Ratings via Email

Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VTVT
CUSIPN/A
Phone336-841-0300

Debt

Debt-to-Equity Ratio-0.10%
Current Ratio0.76%
Quick Ratio0.76%

Price-To-Earnings

Trailing P/E Ratio-1.25
Forward P/E Ratio-1.64
P/E GrowthN/A

Sales & Book Value

Annual Sales$290,000.00
Price / Sales235.89
Cash FlowN/A
Price / CashN/A
Book Value($4.60) per share
Price / Book-0.45

Profitability

EPS (Most Recent Fiscal Year)($1.67)
Net Income$-16,140,000.00
Net Margins-5,547.77%
Return on EquityN/A
Return on Assets-47.47%

Miscellaneous

Employees56
Outstanding Shares32,810,000

How to Become a New Pot Stock Millionaire

vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics (NASDAQ:VTVT) announced its quarterly earnings data on Tuesday, February, 27th. The biotechnology company reported ($0.44) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.03. The biotechnology company had revenue of $0.23 million for the quarter, compared to analysts' expectations of $0.10 million. View vTv Therapeutics' Earnings History.

When is vTv Therapeutics' next earnings date?

vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for vTv Therapeutics.

What price target have analysts set for VTVT?

8 brokerages have issued twelve-month price objectives for vTv Therapeutics' shares. Their predictions range from $4.00 to $28.00. On average, they expect vTv Therapeutics' share price to reach $14.7143 in the next twelve months. View Analyst Ratings for vTv Therapeutics.

Are investors shorting vTv Therapeutics?

vTv Therapeutics saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 1,711,237 shares, an increase of 49.8% from the March 15th total of 1,142,669 shares. Based on an average trading volume of 205,285 shares, the short-interest ratio is presently 8.3 days. Currently, 24.6% of the company's stock are sold short.

Who are some of vTv Therapeutics' key competitors?

Who are vTv Therapeutics' key executives?

vTv Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey B. Kindler, Exec. Chairman (Age 62)
  • Mr. Stephen L. Holcombe, Pres & CEO (Age 61)
  • Mr. Rudy C. Howard B.A., CPA, Exec. VP & CFO (Age 60)
  • Dr. Larry Douglas Altstiel, Exec. VP & Chief Medical Officer (Age 68)
  • Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Has vTv Therapeutics been receiving favorable news coverage?

Headlines about VTVT stock have trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. vTv Therapeutics earned a media sentiment score of 0.14 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.87 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of vTv Therapeutics?

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $2.0850.

How big of a company is vTv Therapeutics?

vTv Therapeutics has a market capitalization of $69.23 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-16,140,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. vTv Therapeutics employs 56 workers across the globe.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PKWY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]


MarketBeat Community Rating for vTv Therapeutics (VTVT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  313
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

vTv Therapeutics (NASDAQ:VTVT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for vTv Therapeutics in the last 12 months. Their average twelve-month price target is $14.7143, suggesting that the stock has a possible upside of 605.72%. The high price target for VTVT is $28.00 and the low price target for VTVT is $4.00. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.252.862.803.00
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.7143$18.1667$16.00$16.50
Price Target Upside: 605.72% upside179.49% upside261.17% upside289.15% upside

vTv Therapeutics (NASDAQ:VTVT) Consensus Price Target History

Price Target History for vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics (NASDAQ:VTVT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2018Roth CapitalDowngradeBuy -> Neutral$18.00 -> $17.00HighView Rating Details
4/10/2018Northland SecuritiesDowngradeOutperform -> Market Perform$28.00HighView Rating Details
4/10/2018Seaport Global SecuritiesDowngradeBuy -> NeutralHighView Rating Details
4/10/2018Piper JaffrayDowngradeOverweight -> Neutral$4.00HighView Rating Details
4/10/2018Stifel NicolausDowngradeBuy -> HoldHighView Rating Details
12/21/2017Canaccord GenuitySet Price TargetBuy$15.00LowView Rating Details
11/8/2017CitigroupReiterated RatingaddN/AView Rating Details
8/4/2017HC WainwrightSet Price TargetBuy$13.00LowView Rating Details
(Data available from 4/21/2016 forward)

Earnings

vTv Therapeutics (NASDAQ:VTVT) Earnings History and Estimates Chart

Earnings by Quarter for vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics (NASDAQ:VTVT) Earnings Estimates

2018 EPS Consensus Estimate: ($1.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.45)($0.45)($0.45)
Q2 20181($0.26)($0.26)($0.26)
Q3 20181($0.18)($0.18)($0.18)
Q4 20181($0.16)($0.16)($0.16)

vTv Therapeutics (NASDAQ VTVT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018        
2/27/2018Q4 2017($0.41)($0.44)$0.10 million$0.23 millionViewN/AView Earnings Details
11/1/2017Q3 2017($0.40)($0.38)$0.19 million$0.02 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.43)($0.4090)$0.19 million$0.01 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.4430)($0.4350)$0.20 million$0.03 millionViewN/AView Earnings Details
2/27/2017Q4 2016($0.14)($0.42)$15.20 million$0.04 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.42)($0.41)$0.10 million$0.04 millionViewN/AView Earnings Details
8/2/2016Q2 2016($0.58)($0.47)$0.18 millionViewN/AView Earnings Details
5/12/2016Q1($0.54)($0.42)$0.38 millionViewN/AView Earnings Details
3/1/2016Q4($0.47)($0.35)$0.03 million$0.23 millionViewN/AView Earnings Details
11/12/2015Q3 2015($0.45)($0.49)$0.13 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

vTv Therapeutics (NASDAQ:VTVT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

vTv Therapeutics (NASDAQ VTVT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 11.20%
Insider Trading History for vTv Therapeutics (NASDAQ:VTVT)
Institutional Ownership by Quarter for vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics (NASDAQ VTVT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/26/2017Ronald O PerelmanMajor ShareholderBuy50,000$4.03$201,500.00View SEC Filing  
12/7/2017Paul G SavasDirectorBuy15,000$4.56$68,400.0081,781View SEC Filing  
8/22/2017Ronald O PerelmanMajor ShareholderBuy20,000$4.57$91,400.00View SEC Filing  
8/16/2017Ronald O PerelmanMajor ShareholderBuy10,000$4.97$49,700.00View SEC Filing  
8/15/2017Ronald O PerelmanMajor ShareholderBuy50,000$4.72$236,000.00View SEC Filing  
8/11/2017Ronald O PerelmanMajor ShareholderBuy85,000$4.13$351,050.00View SEC Filing  
5/15/2017Paul G SavasDirectorBuy3,000$5.18$15,540.0069,881View SEC Filing  
3/31/2017Paul G SavasDirectorBuy10,000$6.50$65,000.0066,435View SEC Filing  
5/27/2016Paul G SavasDirectorBuy6,000$5.67$34,020.0058,781View SEC Filing  
5/24/2016Paul G SavasDirectorBuy1,259$5.26$6,622.3452,526View SEC Filing  
4/8/2016Ronald O PerelmanMajor ShareholderBuy10,000$4.99$49,900.00View SEC Filing  
4/5/2016Ronald O PerelmanMajor ShareholderBuy400,000$5.20$2,080,000.00View SEC Filing  
3/28/2016Paul G SavasDirectorBuy10,000$5.35$53,500.0046,522View SEC Filing  
3/24/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.64$56,400.00View SEC Filing  
3/7/2016Paul G SavasDirectorBuy15,000$5.82$87,300.0030,000View SEC Filing  
2/12/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.83$58,300.00View SEC Filing  
2/5/2016Ronald O PerelmanMajor ShareholderBuy10,000$6.43$64,300.00View SEC Filing  
2/4/2016Ronald O PerelmanMajor ShareholderBuy20,000$6.05$121,000.00View SEC Filing  
1/13/2016Ronald O PerelmanMajor ShareholderBuy15,000$6.41$96,150.00View SEC Filing  
12/18/2015Ronald O PerelmanMajor ShareholderBuy15,000$6.40$96,000.00View SEC Filing  
12/15/2015Noel Joseph SpiegelDirectorBuy5,710$6.20$35,402.006,000View SEC Filing  
10/2/2015Ronald O PerelmanMajor ShareholderBuy30,000$6.26$187,800.00View SEC Filing  
9/28/2015Ronald O PerelmanMajor ShareholderBuy40,000$6.04$241,600.00View SEC Filing  
9/25/2015Paul G SavasDirectorBuy5,000$6.62$33,100.0020,000View SEC Filing  
9/22/2015Ronald O PerelmanMajor ShareholderBuy24,000$6.82$163,680.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

vTv Therapeutics (NASDAQ VTVT) News Headlines

Source:
DateHeadline
Bargain hunters in vTv Therapeutics (+78%) could face capital raise-stoked volatilityBargain hunters in vTv Therapeutics (+78%) could face capital raise-stoked volatility
seekingalpha.com - April 18 at 4:41 PM
vTv Therapeutics shares nearly double following HQ newsvTv Therapeutics shares nearly double following HQ news
www.bizjournals.com - April 18 at 4:41 PM
Bargain hunters jump into vTv Therapeutics, shares up 71%Bargain hunters jump into vTv Therapeutics, shares up 71%
seekingalpha.com - April 17 at 4:50 PM
VTv Therapeutics shares surge 40 percentVTv Therapeutics shares surge 40 percent
finance.yahoo.com - April 17 at 4:50 PM
vTv Therapeutics Fails Late-Stage Alzheimers Study; Is There A Chance For A Comeback?vTv Therapeutics Fails Late-Stage Alzheimer's Study; Is There A Chance For A Comeback?
seekingalpha.com - April 16 at 4:23 PM
vTv Therapeutics (VTVT) Short Interest UpdatevTv Therapeutics (VTVT) Short Interest Update
www.americanbankingnews.com - April 14 at 2:29 AM
Zacks: Analysts Anticipate vTv Therapeutics (VTVT) Will Post Quarterly Sales of $3.14 MillionZacks: Analysts Anticipate vTv Therapeutics (VTVT) Will Post Quarterly Sales of $3.14 Million
www.americanbankingnews.com - April 14 at 1:47 AM
vTv Therapeutics (VTVT) Rating Increased to Hold at Zacks Investment ResearchvTv Therapeutics (VTVT) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 13 at 1:34 PM
 Analysts Anticipate vTv Therapeutics (VTVT) to Post -$0.37 EPS Analysts Anticipate vTv Therapeutics (VTVT) to Post -$0.37 EPS
www.americanbankingnews.com - April 12 at 11:14 PM
UPDATE: Seaport Global Securities Downgrades vTv Therapeutics (VTVT) to NeutralUPDATE: Seaport Global Securities Downgrades vTv Therapeutics (VTVT) to Neutral
www.streetinsider.com - April 12 at 10:23 AM
FY2019 EPS Estimates for vTv Therapeutics (VTVT) Decreased by AnalystFY2019 EPS Estimates for vTv Therapeutics (VTVT) Decreased by Analyst
www.americanbankingnews.com - April 12 at 8:04 AM
Q1 2018 EPS Estimates for vTv Therapeutics Decreased by Seaport Global Securities (VTVT)Q1 2018 EPS Estimates for vTv Therapeutics Decreased by Seaport Global Securities (VTVT)
www.americanbankingnews.com - April 12 at 7:24 AM
VTv Therapeutics stock continues to take a hit on failed Alzheimers studyVTv Therapeutics stock continues to take a hit on failed Alzheimer's study
www.bizjournals.com - April 11 at 4:27 PM
Equities Analysts Issue Forecasts for vTv Therapeutics FY2021 Earnings (VTVT)Equities Analysts Issue Forecasts for vTv Therapeutics' FY2021 Earnings (VTVT)
www.americanbankingnews.com - April 11 at 9:25 AM
vTv Therapeutics Crashes on Alzheimer's Drug Study FailurevTv Therapeutics Crashes on Alzheimer's Drug Study Failure
finance.yahoo.com - April 10 at 4:26 PM
Stifel Sees Challenging Road Ahead For vTv Therapeutics After Failed Alzheimers TrialStifel Sees Challenging Road Ahead For vTv Therapeutics After Failed Alzheimer's Trial
finance.yahoo.com - April 10 at 4:26 PM
Mid-Afternoon Market Update: Dow Rises 460 Points; vTv Therapeutics Shares Fall After Failed Alzheimers TrialMid-Afternoon Market Update: Dow Rises 460 Points; vTv Therapeutics Shares Fall After Failed Alzheimer's Trial
feeds.benzinga.com - April 10 at 3:28 PM
vTv Therapeutics (VTVT) Cut to Neutral at Roth CapitalvTv Therapeutics (VTVT) Cut to Neutral at Roth Capital
www.americanbankingnews.com - April 10 at 10:25 AM
After-Hours Stock Movers 04/09: (PAY) (WATT) (PME) Higher; (VTVT) (NBEV) (EMKR) Lower (more...)After-Hours Stock Movers 04/09: (PAY) (WATT) (PME) Higher; (VTVT) (NBEV) (EMKR) Lower (more...)
www.streetinsider.com - April 10 at 9:55 AM
vTv Therapeutics Crashes on Alzheimers Drug Study FailurevTv Therapeutics Crashes on Alzheimer's Drug Study Failure
www.zacks.com - April 10 at 9:55 AM
vTv Therapeutics azeliragon flunks late-stage Alzheimers studyvTv Therapeutics' azeliragon flunks late-stage Alzheimer's study
seekingalpha.com - April 10 at 9:55 AM
vTv Therapeutics (VTVT) STEADFAST Phase 3 Study Evaluating Azeliragon Didnt Meet Either Co-primary Efficacy EndpointvTv Therapeutics (VTVT) STEADFAST Phase 3 Study Evaluating Azeliragon Didn't Meet Either Co-primary Efficacy Endpoint
www.streetinsider.com - April 10 at 9:55 AM
Shares of vTv Therapeutics plummet as Alzheimers study disappointsShares of vTv Therapeutics plummet as Alzheimer's study disappoints
finance.yahoo.com - April 10 at 9:55 AM
Vtv Therapeutics price plummets after disappointing trial resultsVtv Therapeutics price plummets after disappointing trial results
finance.yahoo.com - April 10 at 9:55 AM
vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s DiseasevTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s Disease
finance.yahoo.com - April 10 at 9:55 AM
vTv Therapeutics (VTVT) Downgraded by Northland SecuritiesvTv Therapeutics (VTVT) Downgraded by Northland Securities
www.americanbankingnews.com - April 10 at 9:16 AM
vTv Therapeutics (VTVT) Downgraded by Seaport Global SecuritiesvTv Therapeutics (VTVT) Downgraded by Seaport Global Securities
www.americanbankingnews.com - April 10 at 8:29 AM
vTv Therapeutics (VTVT) Lowered to Hold at Stifel NicolausvTv Therapeutics (VTVT) Lowered to Hold at Stifel Nicolaus
www.americanbankingnews.com - April 10 at 7:31 AM
Piper Jaffray Downgrades vTv Therapeutics (VTVT) to HoldPiper Jaffray Downgrades vTv Therapeutics (VTVT) to Hold
www.americanbankingnews.com - April 10 at 7:31 AM
Trading in vTv Therapeutics halted pending newsTrading in vTv Therapeutics halted pending news
seekingalpha.com - April 9 at 4:50 PM
vTv Therapeutics (VTVT) Given Consensus Rating of "Buy" by AnalystsvTv Therapeutics (VTVT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 7 at 3:41 AM
UPDATE: Seaport Global Securities Starts vTv Therapeutics (VTVT) at Buy, Azeliragon is all the RAGEUPDATE: Seaport Global Securities Starts vTv Therapeutics (VTVT) at Buy, 'Azeliragon is all the RAGE'
www.streetinsider.com - April 2 at 9:57 AM
vTv Therapeutics (VTVT) Coverage Initiated at Seaport Global SecuritiesvTv Therapeutics (VTVT) Coverage Initiated at Seaport Global Securities
www.americanbankingnews.com - March 29 at 12:29 PM
 Brokerages Expect vTv Therapeutics Inc (VTVT) Will Announce Quarterly Sales of $4.66 Million Brokerages Expect vTv Therapeutics Inc (VTVT) Will Announce Quarterly Sales of $4.66 Million
www.americanbankingnews.com - March 28 at 1:56 AM
UPDATED: vTv Therapeutics reaches milestone in study of its diabetes drugUPDATED: vTv Therapeutics reaches milestone in study of its diabetes drug
www.bizjournals.com - March 26 at 4:18 PM
vTv Therapeutics reaches milestone in study of its diabetes drugvTv Therapeutics reaches milestone in study of its diabetes drug
finance.yahoo.com - March 26 at 9:55 AM
vTv Therapeutics completes Phase 1b study evaluating TTP399 for the treatment of T1DvTv Therapeutics completes Phase 1b study evaluating TTP399 for the treatment of T1D
seekingalpha.com - March 24 at 4:20 PM
Health Care Sector Update for 03/23/2018: PFE,GSK,PGNX,PACB,VTVT.ONT - NasdaqHealth Care Sector Update for 03/23/2018: PFE,GSK,PGNX,PACB,VTVT.ONT - Nasdaq
www.nasdaq.com - March 23 at 4:21 PM
Health Care Sector Update for 03/23/2018: PGNX,PACB,VTVT.ONT - NasdaqHealth Care Sector Update for 03/23/2018: PGNX,PACB,VTVT.ONT - Nasdaq
www.nasdaq.com - March 23 at 4:21 PM
vTv Therapeutics (VTVT) Reports Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes - StreetInsider.comvTv Therapeutics (VTVT) Reports Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes - StreetInsider.com
www.streetinsider.com - March 23 at 4:21 PM
vTv Therapeutics (VTVT) Reports Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 DiabetesvTv Therapeutics (VTVT) Reports Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
www.streetinsider.com - March 23 at 9:29 AM
vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 DiabetesvTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
finance.yahoo.com - March 23 at 9:28 AM
Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant - BenzingaPair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant - Benzinga
www.benzinga.com - March 22 at 4:23 PM
vTv Therapeutics CEO received 82% increase in compensation in 2017vTv Therapeutics CEO received 82% increase in compensation in 2017
www.bizjournals.com - March 21 at 10:41 AM
UPDATE: Roth Capital Starts vTv Therapeutics (VTVT) at BuyUPDATE: Roth Capital Starts vTv Therapeutics (VTVT) at Buy
www.streetinsider.com - March 16 at 5:23 PM
vTv Therapeutics Inc (VTVT) Receives Consensus Rating of "Buy" from AnalystsvTv Therapeutics Inc (VTVT) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 13 at 3:34 AM
Roth Capital Initiates Coverage on vTv Therapeutics (VTVT)Roth Capital Initiates Coverage on vTv Therapeutics (VTVT)
www.americanbankingnews.com - March 8 at 10:37 AM
vTv Therapeutics Inc (VTVT) Short Interest Up 38.5% in FebruaryvTv Therapeutics Inc (VTVT) Short Interest Up 38.5% in February
www.americanbankingnews.com - March 4 at 1:20 AM
Zacks Investment Research Lowers vTv Therapeutics (VTVT) to SellZacks Investment Research Lowers vTv Therapeutics (VTVT) to Sell
www.americanbankingnews.com - March 3 at 12:00 PM
vTv Therapeutics Reports 2017 Fourth Quarter and Full Year Financial and Operational Results and Recent HighlightsvTv Therapeutics Reports 2017 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
finance.yahoo.com - February 28 at 9:26 AM

SEC Filings

vTv Therapeutics (NASDAQ:VTVT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

vTv Therapeutics (NASDAQ:VTVT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

vTv Therapeutics (NASDAQ VTVT) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.